SLC2A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL126018	0.36	11/20
SCHEMBL92770	0.59	9/20
Crisnatol (SCHEMBL3883)	0.61	8/20
SCHEMBL127496	0.46	8/20
SCHEMBL7995	0.59	7/20
Emetine (SCHEMBL56277)	1.00	5/20
Cephaeline (SCHEMBL181711)	0.89	5/20
SCHEMBL253356	0.36	5/20
SCHEMBL302998	0.74	4/20
SCHEMBL302999	0.74	4/20
SCHEMBL304308	0.74	4/20
SCHEMBL304309	0.74	4/20
SCHEMBL190426	0.60	4/20
SCHEMBL178862	0.52	4/20
SCHEMBL202923	0.51	4/20
SCHEMBL250447	0.45	4/20
SCHEMBL172343	0.41	4/20
Hydrochloric Acid (SCHEMBL122278)	0.41	4/20
SCHEMBL218100	0.40	4/20
SCHEMBL251972	0.37	4/20

Clinical trials — most relevant to SLC2A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Anti-diabetic Drugs on Glycemic Variability	PHASE4	COMPLETED
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	PHASE4	COMPLETED
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	PHASE4	COMPLETED
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration	PHASE4	COMPLETED
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes	PHASE4	COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness	PHASE4	WITHDRAWN
Reformulated F75 Milk to Treat Severe Acute Malnutrition	PHASE2/PHASE3	COMPLETED
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin	PHASE2/PHASE3	UNKNOWN
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	PHASE2	COMPLETED
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC	PHASE2	UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
PK and PD of YG1699 in CKD Patients With Diabetes	PHASE1	NOT_YET_RECRUITING
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
Sodium Lactate Infusion in GLUT1DS Patients	EARLY_PHASE1	COMPLETED
SLC2A1 Variants and Diabetic Nephropathy	nan	COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis	nan	RECRUITING
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome	nan	SUSPENDED
Clinical Utility of Breath Tests in GI	nan	COMPLETED
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients	nan	COMPLETED
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography	nan	NOT_YET_RECRUITING
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome	nan	ACTIVE_NOT_RECRUITING
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus	nan	COMPLETED
The Effect of Artificial Sweeteners on Blood Glucose Response	nan	WITHDRAWN
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes	nan	UNKNOWN
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults	nan	COMPLETED
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC2A1 binder may also engage these)

Protein	Name	Similarity
P79365	—	1.000	P79365 →
P13355	—	1.000	P13355 →
P17809	—	1.000	P17809 →
P46896	—	1.000	P46896 →
P11167	—	1.000	P11167 →
P27674	—	1.000	P27674 →
P20303	—	1.000	P20303 →
O62787	—	1.000	O62787 →
P47843	—	1.000	P47843 →
P58352	—	1.000	P58352 →
SLC2A3	Solute carrier family 2, facilitated glucose transporter member 3	0.999	landscape →
Q5R608	—	0.998	Q5R608 →
Q07647	—	0.998	Q07647 →
Q863Y9	—	0.996	Q863Y9 →
P22732	—	0.995	P22732 →
P47842	—	0.995	P47842 →
P28568	—	0.995	P28568 →
P12336	—	0.995	P12336 →
Q8WMN1	—	0.994	Q8WMN1 →
Q9XSC2	—	0.994	Q9XSC2 →
P32037	—	0.993	P32037 →
P43427	—	0.993	P43427 →
Q5RET7	—	0.992	Q5RET7 →
Q90592	—	0.991	Q90592 →
Q27994	—	0.991	Q27994 →
P58353	—	0.991	P58353 →
Q9WV38	—	0.990	Q9WV38 →
P14246	—	0.989	P14246 →
SLC2A2	Solute carrier family 2, facilitated glucose transporter member 2	0.988	landscape →
O62786	—	0.988	O62786 →